- Home
- EXEL vs ABVX Comparison
EXEL vs ABVX Comparison
Compare EXEL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXEL | ABVX |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.2B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | ABVX |
|---|---|---|
| Price | $43.87 | $125.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 11 |
| Target Price | $46.60 | ★ $130.09 |
| AVG Volume (30 Days) | ★ 2.7M | 960.7K |
| Earning Date | 02-10-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $2,320,126,000.00 | $6,231,374.00 |
| Revenue This Year | $14.86 | $6.80 |
| Revenue Next Year | $14.93 | N/A |
| P/E Ratio | $15.36 | ★ N/A |
| Revenue Growth | ★ 6.98 | N/A |
| 52 Week Low | $32.38 | $4.77 |
| 52 Week High | $49.62 | $148.83 |
Technical Indicators
Market Signals| Indicator | EXEL | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 57.81 |
| Support Level | $40.92 | $115.93 |
| Resistance Level | $44.28 | $125.48 |
| Average True Range (ATR) | 1.48 | 4.82 |
| MACD | 0.03 | 1.33 |
| Stochastic Oscillator | 70.53 | 96.87 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.